An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
Background: Gene therapies can treat, prevent, or cure a disease by changing the expression of a person’s genes. They are an innovative strategy for treating genetic disorders; however, they are still emerging on the market access and in the healthcare system. Health technology assessment (HTA) agen...
Saved in:
| Main Authors: | Michał Pochopień, Ewelina Paterak, Emilie Clay, Justyna Janik, Samuel Aballea, Małgorzata Biernikiewicz, Mondher Toumi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2021.2002006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs
by: Hubert Polek, et al.
Published: (2023-12-01) -
Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease
by: Michal Pochopien, et al.
Published: (2024-04-01) -
Health economic evaluation of gene replacement therapies: methodological issues and recommendations
by: Samuel Aballéa, et al.
Published: (2020-01-01) -
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01) -
Validating the Predictions of a Dynamic Transmission Model Using Real-World Data from a Universal Varicella Vaccination Program in Germany
by: Iwona Żerda, et al.
Published: (2025-05-01)